A Multicenter, Open-Label Study to Evaluate the Long Term Efficacy, Safety, and Tolerability of Repeated Administration of Adalimumab in Subjects With Crohn's Disease
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 05 Aug 2017
At a glance
- Drugs Adalimumab (Primary)
- Indications Crohn's disease
- Focus Registrational; Therapeutic Use
- Sponsors AbbVie
- 13 Jun 2017 This trial is completed in Slovakia.
- 31 Jan 2017 Planned End Date changed from 1 Oct 2017 to 1 Jan 2018.
- 31 Jan 2017 Planned primary completion date changed from 1 Jan 2017 to 1 Oct 2017.